RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:A little more information wouldn't be bad!Redbaron2211 wrote: Sally the difference is my logic is not based on rumors. I'm disregarding them as things can change at the blink of an eye. Maybe the CEO of Sanofi realized yes we do need a device. Looking at what's in front of us I see Sanofi being granted fast track designation to factor VIII for treating hemophilia and multiple Sanofi connections included in our recent additions to SAB and BoD.
Tell me why on earth would a 19 year vetern of Sanofi be added to the SAB if they had no interest in Sernova?
All I know is Sanofi is interested in both Sernova, hemophilia and other indications. I also know that no one on these forums is privy to what is actually happening behind NDAs and we can't expect to hear anything from the company.
So I just encourage others to keep an open mind it will likely surprise us all.
Red Sanofi is moving away from diabetes research and as an indication . Shultz was in charge of the diabetes collaboration . Basically they just shelved her position .
My statements are not rumours . You saying Sanofi is interested because an employee of theirs is on the advisory board is pure speculation . Red tell me this why did Sanofi end their collabrativE relationship won't Evotec who has the leading B islets stem cells after years of promising development . They just walked away from it and Hudson is focussing on more lucrative cancer drugs . This is a fact not rumour . Sanofi is not kicking the tires .
Sally